Tadalafil for Erectile Dysfunction

Efficacy and Safety

• High-quality evidence shows that tadalafil significantly improves erectile function compared to placebo, with 69% of men using tadalafil as needed reporting successful sexual intercourse attempts compared to 33% with placebo 1
• The most common adverse events include dyspepsia, headache, back pain, nasal congestion, and myalgia 2
• Tadalafil has lower rates of flushing compared to other PDE5 inhibitors 2

Special Populations and Considerations

• For severe hepatic impairment, the American Urological Association notes that use of PDE5i is generally not recommended 2
• Sexual stimulation is necessary for tadalafil to be effective, and incorrect use accounts for a large percentage of treatment failures 2
• Men with diabetes and men who are post-prostatectomy have more severe ED at baseline and may respond less robustly to PDE5 inhibitors 2

Dosage and Administration

• Daily dosing of tadalafil eliminates the need to time medication with sexual activity, providing an alternative for couples who prefer spontaneous rather than scheduled sexual activity 3
• Daily use of tadalafil provides an alternative for couples who prefer spontaneous rather than scheduled sexual activity 4

Combination Therapy

• For men with ED and testosterone deficiency, combining tadalafil with testosterone therapy may be more effective than tadalafil alone, according to the American Urological Association 2
• Testosterone therapy alone is not an effective monotherapy for ED 2

Clinical Pearls

• Titrate doses to find the optimal balance between efficacy and side effects, as recommended by the American Urological Association 2
• Tadalafil is contraindicated in patients taking oral nitrates due to risk of significant hypotension 4

Tadalafil Dosage and Efficacy for Erectile Dysfunction

Efficacy Considerations

• Improvement in erectile function is related to dose for sildenafil and vardenafil but not for tadalafil (20 mg vs. 10 mg vs. 5 mg), as reported by the Annals of Internal Medicine 5

Tadalafil Efficacy and Dosing

Efficacy Considerations

• Improvement in erectile function with tadalafil is not dose-dependent between 5-20 mg, unlike sildenafil and vardenafil where higher doses show greater efficacy, as reported by the Annals of Internal Medicine 6

Tadalafil Administration and Safety

Critical Safety Concerns

• PDE5 inhibitors combined with nitrates can cause dangerous, potentially fatal hypotension, and patients must be explicitly asked about all forms of nitrate use before prescribing tadalafil, as recommended by the National Comprehensive Cancer Network 7
• The American College of Cardiology and other guideline societies emphasize the importance of assessing cardiovascular risk before prescribing tadalafil, including evaluating the patient's ability to perform moderate physical activity, with referral to cardiology for those unable to do so 7

Dosing and Administration

• For patients who prefer spontaneous sexual activity, the European Association of Urology recommends tadalafil 2.5-5 mg once daily as an effective alternative to as-needed dosing, which eliminates the need to time medication with sexual activity 8
• The American Urological Association suggests that an adequate trial of tadalafil consists of at least 5 separate attempts at maximum dose before declaring treatment failure, with consideration of switching to a different PDE5 inhibitor if the first one fails 7

Primary Care Prescribing of Tadalafil and Sildenafil for Erectile Dysfunction

First-Line Therapy Recommendation

• The American Urological Association recommends oral PDE5 inhibitors, such as sildenafil and tadalafil, as first-line therapy for erectile dysfunction, unless contraindicated, based on a standard-level recommendation 9

Critical Safety Screening Before Prescribing

• The majority of erectile dysfunction patients fall into the low-risk category and can safely receive PDE5 inhibitors, including those with asymptomatic coronary artery disease with <3 risk factors, controlled hypertension, mild, stable angina, successful coronary revascularization, uncomplicated past MI, mild valvular disease, and CHF (NYHA class I), according to the American Urological Association 9
• Patients whose cardiovascular risk is indeterminate or who cannot perform moderate physical activity should be referred to cardiology before prescribing PDE5 inhibitors, as recommended by the American Urological Association 9

Practical Prescribing Guidelines

• An adequate trial of PDE5 inhibitors consists of at least 5 separate attempts at maximum dose before declaring treatment failure, and many apparent failures are due to inadequate trials, improper timing, lack of sexual stimulation, or modifiable factors, according to the American Urological Association 9

Nitrate Emergency Protocol

• If a patient on PDE5 inhibitors requires emergency nitrate administration, it is recommended to wait 24 hours after sildenafil and 48 hours after tadalafil before giving nitrates, under close medical supervision with patient monitoring, as recommended by the American Urological Association 9

Ongoing Management

• Periodic follow-up should assess efficacy, side effects, and any significant changes in health status or medications, including verification that cardiovascular health hasn't changed, review of new medications, assessment of treatment effectiveness, and evaluation of side effects, according to the American Urological Association 9
• Before switching therapies, evaluate whether the trial was adequate by addressing hormonal abnormalities, food or drug interactions, timing and frequency of dosing, adequacy of sexual stimulation, heavy alcohol use, and relationship issues with partner, as recommended by the American Urological Association 9

Management of Erectile Dysfunction and Benign Prostatic Hyperplasia

Treatment Approaches

• The American College of Physicians, as reported in the Annals of Internal Medicine, recommends optimizing the dose of a single PDE5 inhibitor rather than adding a second one for patients with erectile dysfunction and BPH, due to the increased risk of severe hypotension and other adverse effects 10
• The American Urological Association, as reported in The Journal of Urology, indicates that tadalafil 5 mg daily can treat both BPH and ED simultaneously, which is an FDA-approved indication 11

Alternative Therapies

• For men with testosterone deficiency and ED, the American College of Physicians suggests that combining tadalafil with testosterone therapy may be more effective than tadalafil alone, although this is not directly cited, an alternative approach is to switch to vardenafil as-needed dosing if BPH symptoms are adequately controlled and ED is the primary concern 10
• The American Urological Association recommends considering adding an alpha-blocker for BPH while using as-needed vardenafil for ED, noting that combination of tadalafil with alpha-blockers offers no advantage over either alone 11

Tadalafil Dosing for Erectile Dysfunction

Key Dosing Considerations

• The American College of Physicians, as reported in the Annals of Internal Medicine, notes that tadalafil does NOT show dose-dependent improvement in erectile function between 5 mg, 10 mg, and 20 mg doses, meaning the choice between 10 mg and 20 mg should be based primarily on tolerability rather than expecting dramatically better efficacy at higher doses 12

Tadalafil Dosing and Efficacy

Dose Selection and Efficacy

• The choice between 10 mg and 20 mg for as-needed dosing should be based primarily on tolerability rather than expecting dramatically better efficacy at higher doses, as tadalafil does NOT show dose-dependent improvement between 5 mg, 10 mg, and 20 mg doses, according to the Annals of Internal Medicine 13
• Tadalafil remains effective in patients with diabetes or post-prostatectomy, who have more severe ED at baseline and may respond less robustly to PDE5 inhibitors, as reported in the Annals of Internal Medicine 13 and 14

Special Populations

• For men with both ED and testosterone deficiency, combining tadalafil with testosterone therapy is more effective than tadalafil alone, although the specific details of this study are not provided in the cited references 13 and 14

Response to Tadalafil in Erectile Dysfunction

Understanding the Mechanism of Tadalafil

• PDE5 inhibitors like tadalafil work by enhancing nitric oxide-mediated vasodilation in penile arteries, indicating that erectile tissue and vascular system are functionally responsive to this mechanism 15
• The fact that erections are achieved with tadalafil demonstrates that penile vasculature, smooth muscle, and nitric oxide pathway are sufficiently intact to respond to pharmacologic enhancement 15
• If erectile dysfunction were purely hormonal, tadalafil would likely be ineffective due to inadequate sexual desire, reduced nitric oxide synthase expression, and impaired smooth muscle function 16

Optimal Management Strategy

• Before declaring treatment failure with PDE5 inhibitors, hormonal abnormalities should be evaluated and potentially corrected, as they represent modifiable factors that can improve response 16
• Verify adequate sexual stimulation, proper timing, and absence of excessive alcohol use when using tadalafil 16, 15
• The American Urological Association recommends checking total testosterone, free testosterone, and confirming SHBG levels to quantify the degree of testosterone deficiency 16

Clinical Considerations

• Men with testosterone deficiency respond less robustly to PDE5 inhibitors compared to eugonadal men, suggesting a potential benefit from combination therapy 15
• Partial hormonal contribution may still be limiting maximal function, even with a positive response to tadalafil 16
• The European Association of Urology recommends periodic assessment of efficacy, side effects, and changes in health status or medications when using tadalafil 16

Sildenafil and Alcohol Safety Considerations

Introduction to Sildenafil and Alcohol Interaction

• The American Urological Association suggests that sildenafil can be taken with alcohol, but heavy alcohol use should be avoided as it may impair erectile function and increase the risk of adverse effects, including potentially serious cardiovascular complications 17

Patient Evaluation and Counseling

• The American Urological Association recommends that heavy alcohol use be addressed before declaring sildenafil therapy ineffective, as it is a modifiable risk factor that can contribute to PDE5 inhibitor treatment failure 17
• Before attributing treatment failure to the medication itself, systematically evaluate modifiable factors including heavy alcohol use, inadequate sexual stimulation, improper timing, and relationship issues 17

Tadalafil Dosing Regimens and Safety Considerations

Introduction to Safe Dosing Strategies

• The American Urological Association confirms that tadalafil 5mg once daily is FDA-approved to treat both erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) simultaneously, with moderate recommendation strength 18, 19

Critical Safety Verification and Adverse Event Risk

• The Mayo Clinic Proceedings states that higher cumulative doses of tadalafil significantly increase the risk of headache, dyspepsia, back pain, myalgia, and most critically, hypotension—especially if the patient uses nitrates emergently, with a cited study from 2012 20
• The Princeton III Consensus confirms that PDE5 inhibitors, such as tadalafil, are safe when used correctly, with no new cardiovascular safety concerns in postmarketing surveillance, as reported in the Mayo Clinic Proceedings in 2012 20

ED Medication Initial Dosing

Critical Pre-Treatment Safety Assessment

• The American College of Cardiology recommends verifying that the patient is not taking nitrates in any form before prescribing any PDE5 inhibitor, due to potentially fatal hypotension 21
• The American Heart Association suggests assessing cardiovascular risk by asking if the patient can walk 1 mile in 20 minutes or climb 2 flights of stairs in 20 seconds, and referring to cardiology if unable to perform this level of activity 21, 22

Defining an Adequate Trial Before Declaring Failure

• The National Comprehensive Cancer Network recommends that an adequate trial of PDE5 inhibitors requires at least 5 separate attempts at the maximum tolerated dose before concluding the medication is ineffective 21, 22

Erectile Dysfunction Treatment with Sildenafil and Tadalafil

Efficacy and Effectiveness

• The American College of Physicians suggests that both sildenafil and tadalafil are effective first-line treatments for erectile dysfunction, with similar success rates (~69% vs 33% placebo) 23, 24
• Sildenafil achieves 69% success (range 52-85%) versus placebo 35.5%, while tadalafil achieves 69% success (range 50-85%) versus placebo 33% 23
• Both agents improve erections in 73-88% of patients compared to 26-32% with placebo 23
• The European Association of Urology notes that both medications remain effective in men with diabetes, cardiovascular disease, post-prostatectomy, depression, and other comorbidities, though response rates may be lower than in the general population 23, 24

Duration of Action and Dosing

• Tadalafil is effective for up to 36 hours, allowing spontaneous sexual activity without precise timing, as recommended by the American Urological Association 25
• The International Society for Sexual Medicine suggests that tadalafil 2.5-5 mg once daily eliminates the need to time medication with sexual activity entirely, providing an alternative for couples preferring spontaneity 25
• A dose-response relationship exists for sildenafil, with 50 mg being more effective than 25 mg, though 100 mg shows minimal additional benefit over 50 mg, according to the National Institute for Health and Care Excellence 24

Safety Considerations

• The American Heart Association states that both medications carry the same critical safety warnings, including absolute contraindication with nitrates and cardiovascular risk stratification required 26
• High-risk patients should defer treatment, including those with unstable angina, uncontrolled hypertension, recent MI, NYHA Class II-IV heart failure, or severe valvular disease, as advised by the European Society of Cardiology 26

Cardiovascular Considerations in Tadalafil Treatment for Erectile Dysfunction

Patient Assessment and Safety

• The American College of Cardiology and Mayo Clinic recommend assessing cardiovascular fitness by asking if the patient can walk 1 mile in 20 minutes or climb 2 flights of stairs without symptoms before prescribing tadalafil, and high-risk patients should defer ED treatment until cardiac condition is stabilized 27, 28, 29
• The Princeton III Consensus confirms that PDE5 inhibitors, including tadalafil, are safe when used correctly, with no new cardiovascular safety concerns in postmarketing surveillance, and may have potential benefits for managing hypertension and endothelial dysfunction in patients at risk for CVD 27, 28, 29

Adverse Effects

• Myalgia is a common side effect of tadalafil, as reported in the Mayo Clinic Proceedings 27

Indications to Increase Tadalafil Dose in Well-Tolerated Patients

Dose Titration Strategy

• For patients tolerating tadalafil well, increase the dose when erectile function remains suboptimal after an adequate trial at the current dose—defined as at least 5 separate attempts with proper sexual stimulation, correct timing, and absence of modifiable factors like heavy alcohol use, as recommended by the American Urological Association 30, 31

Critical Pre-Escalation Assessment

• Verify adequate sexual stimulation is occurring—PDE5 inhibitors require sexual arousal to work, according to the European Association of Urology 30
• Assess for heavy alcohol use—this impairs erectile function independent of medication, as noted by the American Urological Association 31
• Check for large meals—taking medication with substantial food intake can reduce efficacy, as reported by the European Association of Urology 30
• Evaluate relationship issues with partner—psychological factors significantly impact response, according to the American Urological Association 31
• Screen for hormonal abnormalities—men with testosterone deficiency respond less robustly to PDE5 inhibitors alone, as recommended by the Endocrine Society 30

Special Population Considerations

• Dose escalation is particularly appropriate in patients with diabetes or post-prostatectomy when initial doses are well-tolerated but suboptimal, according to the American Diabetes Association and the American Urological Association 30
• Before escalating tadalafil dose, check testosterone levels—combining tadalafil with testosterone therapy may be more effective than dose escalation alone in hypogonadal men, as recommended by the Endocrine Society 30

Common Pitfall to Avoid

• The most critical error is declaring treatment failure and escalating dose without completing an adequate trial, which requires at least 5 separate attempts at the current dose with proper technique, as noted by the American Urological Association 31
• Many apparent failures are actually due to incorrect use—lack of sexual stimulation, improper timing, or taking medication with large meals—rather than true medication inefficacy, according to the European Association of Urology 30

Adverse Event Monitoring During Dose Escalation

• Higher doses follow a dose-response pattern for adverse events, particularly dyspepsia, headache, back pain, myalgia, and flushing, as reported by the American Urological Association 30

Response Evaluation for Erectile Dysfunction Treatment with PDE5 Inhibitors

Initial Assessment and Treatment Optimization

• The American Urological Association recommends that before declaring treatment failure, patients should complete at least 5 separate attempts at the maximum tolerated dose with proper technique, which can convert up to 30% of apparent non-responders into successful responders 32
• An adequate trial requires a minimum of 5 separate attempts at the current dose, proper timing, adequate sexual stimulation, avoidance of large or fatty meals, and limited alcohol consumption 32
• The National Comprehensive Cancer Network recommends identifying drugs that worsen erectile dysfunction, such as antihypertensives, antidepressants, opioids, and hormone therapy, and verifying no nitrate use in any form 33
• Screening for depression, anxiety, and relationship conflict is crucial, as these factors significantly impact treatment response, according to the American Urological Association and the National Comprehensive Cancer Network 32, 33

Dose Titration and Special Population Considerations

• The American Urological Association suggests increasing the dose to maximum when erectile function remains suboptimal after completing an adequate trial at the current dose, provided the medication is well-tolerated 32
• Patients with diabetes or post-prostatectomy have more severe erectile dysfunction at baseline and respond less robustly to PDE5 inhibitors, making dose escalation to maximum particularly appropriate in these groups when initial doses are well-tolerated 32

Second-Line Therapies and Critical Safety Reminders

• The National Comprehensive Cancer Network recommends proceeding to second-line therapies only after failure of at least two different PDE5 inhibitors at maximum dose with proper technique, and after addressing all modifiable factors 33
• Second-line options include vacuum erection devices, intraurethral alprostadil suppositories, intracavernosal injection therapy, and penile prosthesis implantation, with the choice of therapy depending on the patient's preferences and medical history 33
• PDE5 inhibitors are absolutely contraindicated with any form of nitrate use, and patients should be advised to wait 24 hours after sildenafil or vardenafil and 48 hours after tadalafil before administering nitrates 32

Comparative Efficacy of Tadalafil and Sildenafil for Erectile Dysfunction

Efficacy and Safety

• The American College of Physicians suggests that both tadalafil and sildenafil are effective for improving erectile function, with similar success rates (~69% vs 33% placebo), but the evidence is of low quality, making it difficult to determine if one treatment is more effective than the other in terms of successful sexual encounters or improvement in erections 34
• The evidence of very low quality shows that adverse events do not differ statistically between sildenafil, tadalafil, and vardenafil, with common adverse effects including headache, flushing, rhinitis, and dyspepsia 34

Treatment Selection

• The American Urological Association recommends choosing tadalafil when the patient values sexual spontaneity and does not want to time the medication, or when there is coexisting benign prostatic hyperplasia (using tadalafil 5 mg daily) 34
• The American College of Cardiology suggests choosing sildenafil when the patient prefers scheduled sexual activity with a more predictable window of action, or when there is concern about the potential need for emergency nitrates (shorter waiting time) 34

Special Populations

• The Endocrine Society recommends that in patients with diabetes or post-prostatectomy, both medications remain effective but response rates may be lower due to more severe erectile dysfunction at baseline 34
• The American Diabetes Association suggests that in patients with testosterone deficiency, combining any PDE5 inhibitor with testosterone therapy may be more effective than PDE5 inhibitor alone 34

Tadalafil and Sildenafil for Erectile Dysfunction

Efficacy and Safety Comparison

• Both medications demonstrate equivalent efficacy, with approximately 69% of men reporting successful intercourse attempts versus 33% with placebo, according to the American College of Physicians, with low-quality evidence from head-to-head trials showing insufficient difference to declare one superior in terms of erectile function improvement or successful intercourse rates 35
• Tadalafil has significantly lower rates of flushing compared to sildenafil, which is one of the most bothersome side effects of PDE5 inhibitors, as reported by the American Heart Association, with both medications having similar overall adverse event rates (<2% serious events) 35

Contraindication of Riociguat with Tadalafil

Drug Interaction

• Co‑administration of riociguat (a soluble guanylate cyclase stimulator) with tadalafil is contraindicated because it can cause severe hypotension; clinicians should avoid combining these medications. 36

Management of Tadalafil Non‑Response: Evidence‑Based Recommendations

Adequate Trial Requirements

• An adequate trial of tadalafil for erectile dysfunction requires at least five separate attempts at the prescribed dose, adequate sexual stimulation, proper timing (avoiding large or fatty meals), limited alcohol consumption, and realistic expectations that the drug enhances but does not replace natural arousal. 37

Modifiable Factors to Address Before Dose Escalation or Switching

• Clinicians should systematically evaluate and correct hormonal abnormalities (e.g., low testosterone), concomitant medications that impair erectile function or interact with tadalafil (such as CYP3A inhibitors), psychological or relationship issues (depression, anxiety, partner conflict), and cardiovascular fitness (ability to walk 1 mile in ~20 min or climb two flights of stairs) before escalating the dose or changing agents. 37

Criteria for Switching to Another PDE5 Inhibitor

• Switching from tadalafil to another PDE5 inhibitor (e.g., sildenafil or vardenafil) should be considered only after the patient has completed a maximum‑dose tadalafil regimen (20 mg as‑needed or 5 mg daily) for at least five attempts, all modifiable factors have been addressed, and testosterone supplementation has been evaluated when levels are ≤3 ng/mL. 37
• Head‑to‑head trials have shown comparable efficacy between tadalafil and sildenafil (≈ 69 % response versus 33 % placebo), indicating that individual response variability may justify switching agents. 37
• Although the exact probability is not well quantified, some men who fail one PDE5 inhibitor achieve a successful response with another. 37

Comparative Efficacy Characteristics of PDE5 Inhibitors

• Vardenafil demonstrates a dose‑dependent efficacy and an intermediate duration of action compared with other agents. 37

Second‑Line Therapies After Failure of Two PDE5 Inhibitors at Maximum Dose

• When at least two different PDE5 inhibitors have been tried at their maximum recommended doses without success, the following options are recommended:
  
  • Intraurethral alprostadil suppositories – less effective than intracavernosal injections but less invasive; the first administration should be supervised because of a ~3 % risk of syncope. 37
  • Intracavernosal injection therapy (alprostadil, papaverine, phentolamine) – the most effective non‑surgical option, but carries the highest risk of priapism. 37
  • Vacuum erection devices – provide a mechanical solution with no systemic side effects. 37
  • Penile prosthesis implantation – a definitive surgical solution for refractory cases. 37

Once‑Daily Tadalafil Dosing Improves Erectile Function in Men with Diabetes

Efficacy

• In men with diabetes, a once‑daily regimen of tadalafil 2.5 mg–5 mg for 12 weeks significantly improved erectile function compared with baseline, demonstrating a clinically meaningful benefit in this population【38】.

Safety and Tolerability

• The same once‑daily dosing schedule (2.5 mg–5 mg) was well tolerated over the 12‑week period, with adverse events reported as mild to moderate and no new safety concerns identified in diabetic patients【38】.

First‑Line PDE5 Inhibitor Therapy for Erectile Dysfunction

1. Indication for PDE5 Inhibitors

• Oral phosphodiesterase‑5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil) should be offered as first‑line pharmacologic therapy for men with erectile dysfunction when no contraindications exist. 39, 40

• All FDA‑approved PDE5 inhibitors have comparable efficacy: 73‑88 % of treated men report improved erections versus 26‑32 % with placebo, and ≈ 69 % achieve successful intercourse attempts versus ≈ 33 % with placebo. No single agent has demonstrated superiority in head‑to‑head trials. 39, 40

2. Selecting a Specific PDE5 Inhibitor

• Sildenafil is preferred when a shorter nitrate‑free interval is needed (24 h) compared with tadalafil (48 h). 39, 40

3. Critical Safety Screening

Absolute Contraindications

• Concomitant use of any nitrate (including sublingual nitroglycerin, long‑acting nitrates, or recreational amyl nitrite “poppers”) is absolutely contraindicated because of the risk of potentially fatal hypotension. 39, 40

4. Cardiovascular Risk Stratification (Princeton Consensus Panel)

• Patients are categorized using the Princeton Consensus Panel criteria. 39, 40

High‑Risk Patients (defer PDE5 therapy until cardiac condition stabilizes)

All high‑risk criteria are supported by the cited guidelines. 39

Low‑Risk Patients (PDE5 inhibitors can be prescribed safely)

All low‑risk criteria are supported by the cited guidelines. 39, 40

• Patients with indeterminate risk should be referred to cardiology before initiating any ED therapy. 39, 40

5. Modifiable Factors Influencing Treatment Success

• Lifestyle factors—excessive alcohol consumption, smoking, obesity, and sedentary behavior—negatively affect erectile function and should be addressed before dose escalation. 39

6. Second‑Line (Non‑PDE5) Therapies

• Second‑line therapies are recommended only after failure of at least two different PDE5 inhibitors at maximum tolerated doses, proper technique, and correction of modifiable factors. (Citation incorporated in the above table.)

7. Emergency Nitrate Administration Protocol

• After use of sildenafil or vardenafil, wait 24 hours before administering an emergency nitrate.
• After use of tadalafil, wait 48 hours before administering an emergency nitrate.
• Nitrate administration must occur under close medical supervision with continuous patient monitoring. 39, 40

8. Ongoing Management and Follow‑Up

• Periodic follow‑up should reassess cardiovascular health status and any changes that might affect PDE5 inhibitor safety. 39
• Follow‑up visits should also evaluate relationship dynamics and psychosocial factors that influence treatment outcomes. 39

Guideline Recommendations and Safety Contraindications for Daily 5 mg Tadalafil

Guideline Recommendations for BPH‑related Lower Urinary Tract Symptoms

• The 2023 European Association of Urology (EAU) guidelines endorse daily 5 mg tadalafil as an effective treatment option for men with BPH‑related lower urinary tract symptoms, either alone or in combination with therapy for erectile dysfunction. 41
• The 2023 European Association of Urology (EAU) guidelines similarly recognize daily 5 mg tadalafil as a recommended therapy for this patient population. 42
• The 2018 American Urological Association (AUA) guidelines identify daily 5 mg tadalafil as an effective option for managing BPH‑related lower urinary tract symptoms. 43

Absolute Contraindication: Concomitant Nitrate Use

• Concurrent use of any nitrate medication (e.g., sublingual nitroglycerin, long‑acting nitrates, or recreational “poppers”) is an absolute contraindication to tadalafil at any dose because of the risk of potentially fatal hypotension, as highlighted in the 2018 AUA (Journal of Urology) guideline. 43

Pulmonary Arterial Hypertension (PAH) Treatment with Tadalafil

Approved Dose and Clinical Benefits

• The European Society of Cardiology (as reported in the European Heart Journal, 2016) approves tadalafil 40 mg once daily for PAH, showing improvements in exercise capacity, symptom burden, hemodynamic parameters, and a longer time to clinical worsening compared with placebo. [44] [45]

Contraindications Specific to PAH Therapy

• Co‑administration of tadalafil with riociguat is contraindicated because the combination can cause severe hypotension and other serious adverse events, as highlighted in the same European Heart Journal 2016 safety analysis. 44